Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

BRG1 and BRM loss selectively impacts RB and P53, respectively: BRG1 and BRM have differential functions in vivo.

Marquez-Vilendrer SB, Rai SK, Gramling SJ, Lu L, Reisman DN.

Oncoscience. 2016 Dec 21;3(11-12):337-350. doi: 10.18632/oncoscience.333. eCollection 2016.

2.

ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin.

Lyu C, Zhang Y, Zhou X, Lang J.

Exp Ther Med. 2016 Dec;12(6):4067-4071. doi: 10.3892/etm.2016.3863. Epub 2016 Nov 2.

3.

SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer.

Tordella L, Khan S, Hohmeyer A, Banito A, Klotz S, Raguz S, Martin N, Dhamarlingam G, Carroll T, González Meljem JM, Deswal S, Martínez-Barbera JP, García-Escudero R, Zuber J, Zender L, Gil J.

Genes Dev. 2016 Oct 1;30(19):2187-2198. Epub 2016 Oct 13.

4.

Functional redundancy of the Notch pathway in ovarian cancer cell lines.

Silva F, Félix A, Serpa J.

Oncol Lett. 2016 Oct;12(4):2686-2691. Epub 2016 Aug 5.

5.

The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.

Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, Zhang R, Speicher DW.

Mol Cell Proteomics. 2016 Nov;15(11):3348-3360. Epub 2016 Sep 21.

6.

Unsupervised detection of cancer driver mutations with parsimony-guided learning.

Kumar RD, Swamidass SJ, Bose R.

Nat Genet. 2016 Oct;48(10):1288-94. doi: 10.1038/ng.3658. Epub 2016 Sep 12.

PMID:
27618449
7.

miR-31 targets ARID1A and enhances the oncogenicity and stemness of head and neck squamous cell carcinoma.

Lu WC, Liu CJ, Tu HF, Chung YT, Yang CC, Kao SY, Chang KW, Lin SC.

Oncotarget. 2016 Aug 30;7(35):57254-57267. doi: 10.18632/oncotarget.11138.

8.

Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors.

Ayhan A, Mao TL, Suryo Rahmanto Y, Zeppernick F, Ogawa H, Wu RC, Wang TL, Shih IeM.

J Pathol Clin Res. 2015 May 27;1(3):186-93. doi: 10.1002/cjp2.22. eCollection 2015 Jul.

9.

Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.

Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Wu C, Shroff RT, Chen JL, Bekaii-Saab T.

Cancer. 2016 Dec 1;122(23):3657-3666. doi: 10.1002/cncr.30247. Epub 2016 Aug 6.

PMID:
27495988
10.

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.

Kwan SY, Cheng X, Tsang YT, Choi JS, Kwan SY, Izaguirre DI, Kwan HS, Gershenson DM, Wong KK.

Oncotarget. 2016 Aug 30;7(35):56933-56943. doi: 10.18632/oncotarget.10921.

11.

Genetic and molecular changes in ovarian cancer.

Hollis RL, Gourley C.

Cancer Biol Med. 2016 Jun;13(2):236-47. doi: 10.20892/j.issn.2095-3941.2016.0024.

12.

Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies.

Yang L, Wei S, Zhao R, Wu Y, Qiu H, Xiong H.

Sci Rep. 2016 Jun 29;6:28919. doi: 10.1038/srep28919.

13.

Ric-8A gene deletion or phorbol ester suppresses tumorigenesis in a mouse model of GNAQ(Q209L)-driven melanoma.

Patel BR, Tall GG.

Oncogenesis. 2016 Jun 27;5(6):e236. doi: 10.1038/oncsis.2016.45.

14.

Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.

Abou-Taleb H, Yamaguchi K, Matsumura N, Murakami R, Nakai H, Higasa K, Amano Y, Abiko K, Yoshioka Y, Hamanishi J, Koshiyama M, Baba T, Yamada R, Matsuda F, Konishi I, Mandai M.

Oncotarget. 2016 Aug 23;7(34):54758-54770. doi: 10.18632/oncotarget.10181.

15.

Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.

Zhang Q, Yan HB, Wang J, Cui SJ, Wang XQ, Jiang YH, Feng L, Yang PY, Liu F.

Oncotarget. 2016 Jul 19;7(29):46127-46141. doi: 10.18632/oncotarget.10060.

16.

The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.

Kartha N, Shen L, Maskin C, Wallace M, Schimenti JC.

Genetics. 2016 Aug;203(4):1601-11. doi: 10.1534/genetics.115.184879. Epub 2016 Jun 8.

PMID:
27280691
17.

Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.

Cobb LP, Gaillard S, Wang Y, Shih IeM, Secord AA.

Gynecol Oncol Res Pract. 2015 May 12;2:1. doi: 10.1186/s40661-015-0008-z. eCollection 2015.

18.

ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance.

Lee LH, Sadot E, Ivelja S, Vakiani E, Hechtman JF, Sevinsky CJ, Klimstra DS, Ginty F, Shia J.

Hum Pathol. 2016 Jul;53:97-104. doi: 10.1016/j.humpath.2016.02.004. Epub 2016 Mar 2.

PMID:
26980037
19.

Deletion of Arid1a in Reproductive Tract Mesenchymal Cells Reduces Fertility in Female Mice.

Wang X, Khatri S, Broaddus R, Wang Z, Hawkins SM.

Biol Reprod. 2016 Apr;94(4):93. doi: 10.1095/biolreprod.115.133637. Epub 2016 Mar 9.

20.

Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.

Suryo Rahmanto Y, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IeM.

J Biol Chem. 2016 Apr 29;291(18):9690-9. doi: 10.1074/jbc.M115.707612. Epub 2016 Mar 7.

Supplemental Content

Support Center